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ORIGINAL RESEARCH
Objective: Asthma and COPD require different management strategies, but differentiation
in primary care is difficult. This primary care support initiative observed the impact of
spirometry and clinical assessment on the diagnosis of airway disease.
Materials and methods: Of 61 191 patients aged ≥40 years being treated for respiratory
conditions within 1003 UK primary care practices, 43 203 underwent a diagnostic review
including standardized spirometric assessment. The proportion of patients in whom the
diagnosis was changed by the additional information was determined. The relationship of
various patient characteristics was compared with the baseline and review diagnoses and
with any change in diagnosis.
Results: Asthma was initially diagnosed in 43% of patients, COPD in 35%, mixed disease in
9%, and other respiratory condition in 13%. Patients initially diagnosed with asthma, mixed
disease, or another condition were more likely to have their diagnosis changed at review
(54%, 46%, and 63%, respectively) than those initially diagnosed with COPD (14%). A change
from asthma to COPD was associated with male gender, smoking, older age, and reduced
lung function, the opposite being associated with a change from COPD to asthma.
Conclusion: In this study, a clinical review supplemented by additional information including
spirometry highlights apparent mislabeling of significant numbers of patients with chronic
obstructive disease in general practice with significant implications for individual treatment
and healthcare provision. This study shows that the addition of more clinical information can
have a major effect on diagnostic tendency in patients with airway disease. An initial diagnosis
of COPD seems less likely to change following review than an asthma diagnosis. While it is
likely that greater information leads to a more accurate diagnosis, the differential effect of
new information on diagnostic labeling highlights the insecurity of the diagnostic process in
primary care in the UK.
Keywords: COPD, spirometry, guidelines, primary care, diagnosis, asthma
INTRODUCTION
Chronic respiratory diseases are common and account for a large proportion of patients
seen in general practice (Pearson et al 1996). Both asthma and COPD result in
significant morbidity, impaired quality of life, and mortality (Petty 2000; Jacobs et al
2001; Pauwels et al 2001). In addition, both conditions pose a considerable economic
burden for the health system (NIH 1997; Rutten van-Molken and Feenstra 2001).
Airflow limitation is common to both asthma and COPD, but the mechanisms
involved, prognosis, and management strategies differ (ATS 1995; Siafakas 1995;
NIH 1997; The COPD Guidelines Group of the Standards of Care Committee of the
BTS 1997; Pauwels et al 2001; British Guideline on the Management of Asthma
2003). When properly treated, symptomatic asthma will be well controlled in most
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patients, whereas the symptoms of COPD will be, at best,
minimized (McIvor and Chapman 1996).
A crucial precondition for the optimal management of
airways disease is to make a reliable diagnosis (Martinez
1998). The diagnosis of COPD is dependent on objective
demonstration of airflow limitation (forced expiratory
volume [FEV1], FEV1/forced vital capacity [FVC] ratio)
using spirometry. By definition, COPD differs from asthma
as it lacks full reversibility of airflow limitation (Martinez
1998; Pauwels et al 2001); however, even in well-equipped
secondary care clinics, it is often difficult to distinguish
between the two conditions in smokers over the age of 40
(Jans et al 1998), and their differentiation is more
challenging in primary care, where access to or training in
the use of spirometry is often limited. In primary care,
diagnosis was traditionally based on history and physical
examination alone although this is currently changing. This
is a particular problem with older patients in whom clinical
findings may be equivocal, due to multiple pathology, under-
reporting of symptoms, and reduced perception of dyspnea
(Tregonning and Langley 1999). In some cases, the
diagnosis of asthma or COPD can be completely missed
(Renwick and Connolly 1996; McIvor and Tashkin 2001).
Little is known about factors influencing the general
practitioner’s (GP)’s decision in the diagnosis and treatment
of chronic respiratory patients in the absence of spirometry.
It is likely that clinical features specific to COPD, as well
as smoking history, are considered in making a diagnosis
(Griffiths et al 1999), but their validity may have some
limitations (Price and van der Molen 2001). While it is likely
that adding relevant information will improve diagnostic
accuracy, it is equally possible that simply being presented
with extra information encourages change.
The COPD and Asthma Diagnostic/management
REassessment (CADRE) programme considered baseline
information of a primary care audit support initiative
commenced in 1997, at around the time of the first British
Thoracic Society (BTS) COPD guidelines in response to
the low availability of spirometry in primary care. The
initiative offered the chance to observe the impact of adding
further specific clinical assessment and spirometric data to
the pattern of diagnostic labeling by GPs of patients with
obstructive airway diseases throughout the UK. Results in
terms of disease labeling before and after spirometric
assessment from 1997 to 2001 are reported in this paper




The CADRE programme collected data regarding
respiratory patients being managed in primary care practices
across the UK between 1997 and 2001. Practices were
selected if they met the following criteria: a computerized
respiratory register; an asthma-trained practice nurse; GP
commitment to the project; and more than 300 identifiable
respiratory patients over the age of 40 years.
Methods
Data were collected by a team of 40 diploma-qualified
respiratory nurses (National Respiratory Training Centre,
Warwick, UK) employed by an independent contract
company, who were formally seconded and clinically
responsible to each general practice for the purposes of this
programme. The nurses were authorized by each practice
to analyze practice notes and review patients. All therapeutic
decisions remained the responsibility of the prescribing GP
and no patient-identifiable information was removed from
the practice.
The respiratory nurses identified all patients likely to
have obstructive lung disease from practice records based
on the following predefined screening criteria: ≥40 years
old, with more than one prescription for bronchodilators in
the past 12 months; at least one persistent respiratory
symptom; recurrent “chest infections”; or lung function
outside the normal range (as measured by peak expiratory
flow [PEF] or FEV1).
Identified patients were then invited to a review clinic
and, subject to their written informed consent, offered an
additional respiratory assessment by the nurse. Consenting
patients were reassessed by both clinical assessment and
spirometry. In each case, the best of three repeatable
spirometric measurements was used. The clinical assessment
included a specific smoking history, night-time and day-
time symptoms, prior respiratory and allergy history,
medication details, and family history.
The additional clinical and lung-function data were
shared with the GP, who reviewed each patient’s diagnosis
and classified it as one of the following: asthma, COPD,
mixed disease (asthma and COPD), or another respiratory
condition (“other”). The revised diagnosis was recorded in
the database. The GP also adjusted disease management
based on clinical need and the review data as necessary.
Any changes in treatment were recorded in the database,
and these will be reported elsewhere.International Journal of COPD 2006:1(4) 437
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In order to analyze the social status of the sample, the
postcodes of the participating practices were collected and
compared with both the index of multiple social deprivation,
and the associated ranks of the indices. These data were
obtained from publicly available sources and were only
available for English wards.
Ethical and consent approach
This programme began as an audit support initiative within
individual GP practices. The additional assessments offered
were those recommended in guidelines but often not
available in primary care. This was an observational study
with no therapeutic intervention.
While individual data were available to the staff at the
practice for both audit and patient management, only data
that were not patient-identifiable were recorded on the
database for central analysis. The 43 803 patients who
accepted the assessment gave written consent for their data
to be evaluated. The basic demographic data of the 17 388
patients who did not attend assessment were used to confirm
that the population studied was representative of the wider
general practice population. This use of anonymized data
are in line with current guidelines (The Confidentiality and
Security Advisory Group for Scotland 2002).
Data evaluation
The level of baseline medication was used as a crude disease
severity stratification as follows:
• If the initial diagnosis was asthma or mixed disease,
patients were matched to the closest corresponding
treatment step of the BTS asthma guidelines 1993, as
utilized previously (Guidelines on the Management of
Asthma 1993).
• If the initial diagnosis was COPD, patients were matched
to the following medication use scheme, adapted by the
authors from the BTS COPD guidelines (9): Level 1 =
single inhaled bronchodilator; Level 2 = multiple short-
acting bronchodilators (inhaled/oral); Level 3 = level 2
plus long-acting β2-agonist (LABA); Level 4 – addition
of nebulized bronchodilator(s); and level 5 = regular oral
steroids.
Analysis of patient factors associated
with a change in diagnosis
A multiple logistic regression analysis was performed for
each of the baseline and review diagnoses to assess the effect
of various patient characteristics (gender, age, smoking
habits, FEV1, and FEV1/FVC ratio) on a change in diagnosis.
The Hosmer-Lemeshow goodness-of-fit test was used to
test the fit of each model. Variance in the dependent variable




A total of 61 191 patients from 1003 general practices
throughout the UK met the screening criteria; of these,
60 008 (98%) had a baseline diagnosis recorded, and 43 803
(72%) also had a diagnostic review. The number of patients
with both a baseline and review diagnosis was 43 203 (71%),
as 600 patients had a review but no baseline diagnosis.
Of the 1003 practices, 768 (82%) were located in
England and entered the analysis of social deprivation. The
participating practices were located in socially more
deprived wards than the average in England, with 50% of
the participating practices ranking within the lowest 30
percentiles compared with 18% within the highest 30
percentiles. The average index of social deprivation score
of the participating practices (21.7±15.4) was significantly
lower than in all English wards (29.7±18.1; p<0.0001)
(Office for National Statistics 1998).
Baseline characteristics and diagnoses
The 43 203 patients that attended the diagnosis review had
similar baseline characteristics to those initially screened
and included 18 931 (44%) who were labeled as asthma;
14 572 (34%) as COPD; 3979 (9%) as mixed disease; and
5721 (13%) as “other” (Table 1).
The category of “other” included prior labels of
bronchitis, breathlessness, bronchiectasis, cough, chest
infections, shortness of breath, cardiogenic symptoms, and
upper respiratory tract infection. An asthma label was
associated with being female (14 476 patients; 56%), better
lung function (mean FEV1: 1.63 L), younger age (mean 64
years), and non-smokers (3308 [18%] patients). In contrast,
those labeled COPD had a male preponderance (12058
[57%] patients), worse lung function (mean FEV1: 1.26 L),
older age (mean 70 years), and included fewer non-smokers
(9% vs 54% for ex-smokers and 37% for current-smokers).
The mixed disease group was intermediate for each (Table
2).
There was a trend for a worse FEV1 with increasing
treatment intensity, but no correlation with either smoking
status or whether or not the diagnosis was later revised
(Table 3).International Journal of COPD 2006:1(4) 438
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Change in diagnosis
We analyzed only patients with both a baseline and review
diagnosis (n=43203). Patients with an initial diagnostic label
of asthma, mixed disease, or other condition were more
likely to have their diagnosis changed at review (10 228
[54%], 1811 [46%], and 3616 [63%], respectively), than
those initially diagnosed with COPD (2028 [14%]) (Table
4).
Gender, age, smoking status, and lung function were all
statistically significant predictors of a change in diagnosis
for patients originally diagnosed with asthma and COPD
(Tables 4 and 5). For patients originally diagnosed with
asthma, male gender, smoking status (smokers and ex-
smokers), older age, lower FEV1, and a lower FEV1/FVC
were more likely to be associated with a subsequent change
in diagnosis. Conversely, for patients originally diagnosed
with COPD, female gender, a non-smoking status, younger
age, higher FEV1, and a higher FEV1/FVC ratio were more
likely to produce a subsequent change in diagnosis. None
of the potential predictors were statistically significant in
the analysis of a change in diagnosis for the mixed-disease
group.
In patients labeled as having asthma at baseline who
had a change in diagnosis, the change was mainly to COPD
(6272 [61%]) or mixed disease (3474 [34%]). Of the small
proportion of COPD patients in whom the diagnosis was
changed, almost three-quarters were re-labeled as either
mixed disease (847 [42%]) or asthma (648 [32%]). In the
mixed population, the predominant change was to COPD
(1386 [77%]) (Table 6). The diagnostic re-labeling was
independent of the intensity of treatment (Table 3).
DISCUSSION
This study has shown that clinical review augmented by
spirometry for respiratory patients in primary care leads to
a change in diagnostic labeling in a significant proportion
of such patients and that this is independent of current level
of treatment. Before considering the implications of this, it
is worth placing the study in context.
When the BTS COPD guidelines (ATS 1995) were
conceived, it was apparent that access to spirometry in
primary care was limited, and a survey by the BTS COPD
consortium in 1999 confirmed that most had little awareness
of FEV1 as a diagnostic tool in COPD (Halpin and Rudolf
2002). Some in primary care were critical of the guidelines
for relying on spirometry for diagnosis (Nolan and White
1999; White and Nolan 2000). The CADRE programme was





Male 30 955 (50.6) 22 128 (51.3)
Female 30 203 (49.4) 21 045 (48.7)
Age (years); mean (±SD) 66.7 (±11.1) 66.7 (±10.7)
Smoking status
c; n (%)
Never smoked 5853 (14.0) 5805 (14.1)
Ex-smoker 21 364 (51.1) 21 033 (51.0)
Current smoker 14 590 (34.9) 14 373 (34.9)
FEV1 (L)
d; mean (±SD) 1.49 (±0.68) 1.49 (±0.68)
Baseline diagnosis
e; n (%)
Asthma 25 959 (43.3) 18 931 (43.8)
COPD 21 012 (35.0) 14 572 (33.7)
Mixed disease 5501 (9.2) 3979 (9.2)
Other condition 7536 (12.6) 5721 (13.2)
aPatients with diagnosis at both baseline and review visit.
bMissing for 33 patients at baseline and 30 at review.
cMissing for 19 384 patients at baseline and 1992 at review.
dMissing for 24 322 patients at baseline and 6809 at review.
eMissing for 1183 patients at baseline.
Table 2 Patient demographics at baseline by baseline diagnosisa
Asthma COPD Mixed disease Other
(n=25959) (n=21012) (n=5501) (n=7536)
Gender
b, n (%)
Male 11 465 (44.2) 12 058 (57.4) 2765 (50.3) 4030 (53.5)
Female 14 476 (55.8) 8950 (42.6) 2732 (49.7) 3499 (46.5)
Age (years); mean (±SD) 63.5 (±11.5) 70.1 (±9.6) 67.5 (±10.4) 67.2 (±11.1)
Smoking status
c; n (%)
Never smoked 3308 (18.3) 1228 (8.9) 500 (13.3) 773 (13.9)
Ex-smoker 8698 (48.1) 7524 (54.4) 1998 (53.0) 2823 (50.9)
Current smoker 6065 (33.6) 5091 (36.8) 1270 (33.7) 1954 (35.2)
FEV1 (L)
d; mean (±SD) 1.63 (±0.70) 1.26 (±0.59) 1.37 (±0.61) 1.60 (±0.71)
aPatients with missing baseline diagnosis not included (1183).
bMissing for a further 33 patients at baseline.
cMissing for a further 18 776 patients at baseline and 1992 at review.
dMissing for a further 23 600 patients at baseline.International Journal of COPD 2006:1(4) 439
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established as a support service to over 1000 primary care
practices offering spirometry and the services of a specialist
nurse.
The primary care practices tended to be from the lower
social-class areas of the UK (where respiratory diseases are
more prevalent) (White and Nolan 2000), probably
reflecting both the entry requirement for a large number of
respiratory patients on the register and where existing COPD
services are less established. This, along with the age-
selection criterion, will have favored the inclusion of more
COPD than asthma patients, so these data are only applicable
to the age range studied. The high refusal rate could have
biased the generalizability of the findings, but as those
patients who did attend were of similar demographic
characteristics, smoking habits, and diagnoses, this is
probably not a factor. Although funded ultimately by a
pharmaceutical company, the nurses who carried out the
work were employed through a third party, and the clinical
responsibility for responding to the additional information
by deciding whether or not to alter the diagnostic label and/
or treatment remained entirely with the GP. We cannot
dissect out the relative importance of new clinical
information and spirometry in persuading the GP to change
diagnosis, which is a weakness of this study. Finally, no
attempt was made to validate the accuracy of the review
diagnosis. This limited the ability of the study to improve
measurement of disease prevalence but did allow assessment
of factors affecting diagnostic change.
Despite these caveats, this is one of the largest
observational studies of UK practice for a specific condition
and these limitations are unlikely to have influenced a GP’s
decision whether or not to change a diagnosis.
There are few data to show the relative prevalence of
asthma and COPD in the UK population, and those
published do not have any validation of the recorded
diagnosis by means of a clinical assessment (Renwick and
Connolly 1996; Soriano et al 2000, 2002). However, a
common feature is the association of diagnostic inaccuracy
in older people. This study shows a remarkable frequency
of diagnosis change which could challenge the validity of
pharmaco-epidemiological and other studies which have
been based on an unchallenged primary care diagnosis
(Soriano 2002).
Diagnosis was unchanged in 12 544 [86%] COPD
patients. The features associated with a change of diagnosis
from COPD (younger age, a non-smoking status, and better
FEV1) are those features that would, from the known
epidemiology of COPD and asthma, be expected to be more
typical of an asthma population. However, in those with the
most severe disease (FEV1 <1.0 L), 92% were confirmed as
having COPD, suggesting that in the older smoker there
may be some support for those who argue that it is possible
to diagnose COPD without spirometry.
The diagnosis was changed in nearly half those patients
with an initial diagnosis of mixed disease, and in over half
those with an initial label of asthma. Together, these patients
made up over half the cohort. The main shift in diagnosis
was towards COPD, and the factors associated with a change
(increased age, more smoking, lower lung function) are the
opposite of those associated with the change in diagnosis
Table 3 Proportion of never-smokers (as compared to ex-smokers/smokers) at entry, summarized by baseline diagnosis and by
medication level
Characteristic Medication Asthma COPD Mixed disease Other
Level (n=25959) (n=21012) (n=5501) (n=7536)
Proportion (%) of non-smokers 1 13.8 9.3 11.0 12.6
2 18.3 7.8 15.3 13.2
3 19.3 9.9 13.3 17.5
4 20.7 7.0 11.3 14.4
5 23.0 9.3 22.6 18.5
Mean FEV1 (L) 1 1.66 1.35 1.40 1.61
2 1.70 1.22 1.39 1.60
3 1.65 1.24 1.43 1.49
4 1.51 1.00 1.29 1.36
5 1.41 1.09 1.26 1.22
Proportion (%) with change in diagnosis 1 56.7 16.7 53.5 60.8
2 49.9 10.6 49.2 67.5
3 51.4 15.2 44.7 69.1
4 60.1 7.7 43.9 72.8
5 63.4 13.8 41.8 64.6International Journal of COPD 2006:1(4) 440
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Table 4 Summary and analysis of change in diagnosis by individual predictor variables for asthma, COPD, mixed disease, and other
disorders
Asthma No change in diagnosis Change in diagnosis Odds ratio Odds ratio
(n=18931) (n [%]=8643 [45.7]) (n [%]=10288 [54.3]) calculation (95% CI)
N% n%
Gendera
Male 3421 40.7 4983 59.3 Females to males 0.70 (0.66, 0.74); p<0.001
Female 5211 49.6 5298 50.4
Mean age, years (±SD) 62.0 (±11.4) 65.6 (±10.6) Per 10 years 1.35 (1.31, 1.38); p<0.001
Smoking
2
Smokers 2396 39.5 3663 60.5
Ex-smokers 3740 43.0 4952 57.0 Ex-smokers to smokers 0.87 (0.81, 0.93); p<0.001
Non-smokers 2018 61.1 1287 38.9 Non-smokers to smokers 0.42 (0.38, 0.46); p<0.001
FEV1
b, mean (±SD) 1.92 (±0.73) 1.40 (±0.59) Per litre 0.29 (0.28, 0.31); p<0.001
FEV1/FVCc, mean (±SD) 72.8 (±37.4) 60.4 (±14.7) Per 10% 0.52 (0.50, 0.54); p<0.001
1Missing for 7 patients.
2Missing for 173 patients.
3Missing for 402 patients.
4Missing for 2783 patients.
Note: Odds ratios apply to the risk of that variable contributing to a change of diagnosis.
Table 4 (continued)
COPD No change in diagnosis Change in diagnosis Odds ratio Odds ratio




Male 7575 88.5 982 11.5 Females to males 1.63 (1.48, 1.79); p<0.001
Female 4967 82.6 1046 17.4
Mean age, years (±SD) 69.9 (±9.1) 68.4 (±10.0) Per 10 years 0.84 (0.80, 0.89); p<0.001
Smokingb
Smokers 4505 88.5 585 11.5
Ex-smokers 6529 86.8 994 13.2 Ex-smokers to smokers 1.17 (1.05, 1.31); p<0.001
Non-smokers 861 70.2 366 29.8 Non-smokers to smokers 3.27 (2.82, 3.80); p<0.001
FEV1
c, mean (±SD) 1.20 (±0.54) 1.61 (±0.69) Per litre 2.89 (2.67, 3.14); p<0.001
FEV1/FVC
d, mean (±SD) 55.9 (±17.6) 67.6 (±15.3) Per 10% 1.54 (1.46, 1.62); p<0.001
1Missing for 2 patients.
2Missing for 732 patients.
3Missing for 2827 patients.
4Missing for 9703 patients.
Note: Odds ratios apply to the risk of that variable contributing to a change of diagnosis.
Table 4 (continued)
Mixed disease No change in diagnosis Change in diagnosis Odds ratio Odds ratio




Males 1098 54.2 929 45.8 Females to males 0.97 (0.86, 1.10); p=0.66
b
Females 1069 54.8 880 45.2
Mean age, years (±SD) 67.2 (±10.2) 67.7 (±9.9) Per 10 years 1.06 (1.00, 1.13); p=0.07
Smoking
c
Smokers 669 52.7 601 47.3 p=0.129
Ex-smokers 1084 54.3 913 45.7 Ex-smokers to smokers
Non-smokers 290 58.0 210 42.0 Non-smokers to smokers
FEV1
d, mean (±SD) 1.39 (±0.59) 1.35 (±0.62) Per litre 0.90 (0.80, 1.01); p=0.07
FEV1/FVC
e, mean (±SD) 60.8 (±15.4) 60.3 (±15.1) Per 10% 0.98 (0.91, 1.06); p=0.59
1Missing for 3 patients.
2Not significant.
3Missing for 212 patients.
4Missing for 879 patients.
Note: Odds ratios apply to the risk of that variable contributing to a change of diagnosis.International Journal of COPD 2006:1(4) 441
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from COPD to asthma. Of some concern is the observation
that a change in diagnosis is independent of the level of
treatment. Those on high levels therapy who have symptoms
to such an extent that these levels of treatment have been
reached, appear to be just as likely to have their diagnosis
changed. It might be assumed that high levels of treatment
are associated with more robust diagnoses but this is not
the case and, indeed, this pattern fits in with the author’s
own experience.
The diagnostic difficulties of respiratory conditions are
not confined to asthma and COPD. While significant
numbers of patients were switched to a diagnosis of COPD
following clinical assessment and spirometry, there were
significant numbers remaining in the “other” category, with
a wide range of diagnoses suggesting that there is a
substantive lack of precision in the diagnosing of the
“chesty” patient in primary care.
It is intriguing that provision of new information resulted
in such major changes in diagnostic labeling for initial
diagnoses other than COPD. One issue that may have been
related to a high diagnosis of asthma previously as well as
lack of spirometry was the advent of asthma clinics in UK
primary care in the late 1980s and early 1990s as opposed
to obstructive lung disease clinics. This willingness to review
diagnoses happened in the context of the first national COPD
guidelines in the UK and a changing belief that COPD was
no longer a nihilistic diagnosis and that treatment was indeed
different to asthma. This trend in diagnostic review continues
today and supports incentives in UK primary care for
improving diagnostic accuracy in patients with likely
obstructive lung disease.
Finally, the data show that the proportion of patients who
had their diagnosis changed differed very little with regard
to the intensity (high or low) of treatment, perhaps
suggesting that many patients are receiving high-dose
treatment without a firm diagnosis.
If it is accepted that the introduction of more information
is more likely to lead to a more accurate diagnosis, then
these data suggest that spirometry and more focused clinical
information will improve the quality of clinical care in
patients with airways disease.
Changing a diagnosis from asthma to COPD not only
alters the aims of treatment for each patient, but also has
Table 4 (continued)
Other No change in diagnosis Change in diagnosis Odds ratio Odds ratio




Male 1080 34.4 2060 65.6 Females to males 0.80 (0.71, 0.89); p<0.001
Female 1023 39.7 1551 60.3
Mean age, years (±SD) 66.0 (±10.9) 68.1 (±10.4) Per 10 years 1.21 (1.15, 1.27); p<0.001
Smoking
b
Smokers 626 32.0 1328 68.0
Ex-smokers 986 35.0 1835 65.0 Ex-smokers to smokers 0.88 (0.78, 0.99); p<0.001
Non-smokers 404 52.3 369 47.7 Non-smokers to smokers 0.43 (0.36, 0.51); p<0.001
FEV1
c, mean (±SD) 1.85 (±0.75) 1.46 (±0.64) Per litre 0.45 (0.41, 0.49); p<0.0001
FEV1/FVC
d, mean (±SD) 72.5 (±14.7) 61.8 (±14.4) Per 10% 0.58 (0.54, 0.61); p<0.001
1Missing for 7 patients.
2Missing for 173 patients.
3Missing for 402 patients.
4Missing for 2783 patients.
Note: Odds ratios apply to the risk of that variable contributing to a change of diagnosis.
Table 5 Number and proportion (%) of patients whose
diagnosis were changed, as listed by the following variables:
FEV1, age, smoking status, and gender
Variables Baseline diagnosis
Asthma  COPD  Mixed disease
Gender
Male 4983 (59.3) 982 (11.5) 929 (45.8)
Female 5298 (50.4) 1046 (17.4) 880 (55.2)
Age
<60yrs 2948 (44.6) 390 (18.9) 369 (42.5)
>60–<70 yrs 3235 (56.0) 643 (14.1) 600 (45.5)
>70 yrs 4105 (62.7) 995 (12.5) 842 (47.0)
Smoking status
Non smoker 1287 (38.9) 366 (29.8) 210 (42.0)
Ex-smoker 4952 (57.0) 994 (13.2) 913 (45.7)
Smoker 3663 ( 60.5) 585 (11.5) 601 (47.3)
FEV1
<1 L 2430 (79.1) 383 (8.4) 511 (52.2)
>1–<2 L 5209 (60.2) 921 (15.9) 778 (47.3)
>2 L 1397 (31.0) 499 (36.1) 227 (47.7)International Journal of COPD 2006:1(4) 442
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implications about what the patient will be told, thus altering
their expectations. Conversely, although the proportion of
patients whose diagnosis changed from COPD to asthma
was much smaller, the individual benefits for those with a
new diagnosis of asthma will be greater and more realistic.
The overall use of respiratory treatments is well
documented in most practices, and forms a major part of
every GP budget. Prescription data are often associated with
diagnostic Read codes that, presumably, would be based on
the initial diagnosis we recorded. However, the diagnostic
volatility that we have demonstrated implies that any study
attempting to relate prescribing to the current GP diagnostic
code is currently unreliable.
In summary, this study has shown that in older people
with respiratory illnesses, there seems to be a high proportion
of mislabeling. As these are observational data, it is not
possible to determine whether the revised diagnosis was
most influenced by the availability of spirometry, by the
taking of a more structured history by the specialist nurse,
or by the availability of a full smoking history. However,
the diagnostic volatility implies that current patient
management of obstructive airway conditions in primary
care is less than optimal. The CADRE programme’s
provision of an additional expert resource – the respiratory
nurse – along with time to undertake the extra work of
reassessing the patients and perform spirometry seems to
be of value. While such tasks can reasonably be expected
of any respiratory nurse working in primary care, the
resource may not be readily available from the NHS.
However, if patients are to receive the best care, and the
NHS is to make optimal use of its resources, establishing
correct diagnoses using best procedures would seem to be a
good place to begin and supports the recent advent of
initiatives in UK primary care to support this process.
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